TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7816407

Group type: EXPERIMENTAL
Intervention: Evening primrose oil supplements
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: GnRH analogues
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Well-fitting bra
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Analgesia
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Local excision
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 71

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 71
Study: 2836259

Group type: EXPERIMENTAL
Intervention: Fragmin (2 X 2500 anti-Xa units on Day 1 and 1 X 5000 anti-Xa units from Days 2 to 8)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 193

Group type: COMPARATOR
Intervention: heparin-dihydergot (HDHE) (2 X 5000 IU heparin with 0.5 mg DHE from Days 1 to 8)
Number of subjects: 193

Group type: COMPARATOR
Intervention: heparin-dihydergot (HDHE)
Number of subjects: 193
Study: 29129758

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 26654869

Group type: EXPERIMENTAL
Intervention: Intervention booklet group
Number of subjects: 136

Group type: COMPARATOR
Intervention: General information booklet control group
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 136
Study: 24935282

Group type: EXPERIMENTAL
Intervention: FAc 0.2 μg/day
Number of subjects: 953

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 953
Study: 22875911

Group type: EXPERIMENTAL
Intervention: Quantitative RT-PCR monitoring of minimal residual disease (MRD)
Number of subjects: 278
Study: 20362397

Group type: EXPERIMENTAL
Intervention: Diazepam (benzodiazepine) in addition to mechanical physiotherapy and analgesics for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo in addition to mechanical physiotherapy and analgesics for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60
Study: 18456901

Group type: EXPERIMENTAL
Intervention: Therapist-assisted self-administered parent training (SDPT+T)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Waitlist control group (WL)
Number of subjects: 69
Study: 15917061

Group type: EXPERIMENTAL
Intervention: 30 min of self-paced, non-supervised brisk walking, 5 days per week for 12 weeks (n = 21)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group maintaining habitual lifestyle (n = 10)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 31
Study: 14601352

Group type: EXPERIMENTAL
Intervention: Venlafaxine XL (75 mg, with potential dose doubling after 2 weeks)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 10424326

Group type: EXPERIMENTAL
Intervention: Acuvue contact lenses soaked in 0.3% eye drop solutions
Number of subjects: 265

Group type: COMPARATOR
Intervention: Eye drops (0.3% gentamicin, kanamycin, tobramycin, ciprofloxacin, or ofloxacin)
Number of subjects: 265
Study: 8739655

Group type: EXPERIMENTAL
Intervention: Aredia (pamidronate) 90 mg i.v. every 4 weeks
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 1736944

Group type: EXPERIMENTAL
Intervention: NdYAG laser treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (unlased) teeth
Number of subjects: 30
Study: 6496560

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maxzide tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dyazide capsules
Number of subjects: 0
Study: 31489809

Group type: EXPERIMENTAL
Intervention: Polyester pillow
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Latex pillow
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual pillow
Number of subjects: 92
Study: 27452158

Group type: EXPERIMENTAL
Intervention: Pharmacist-physician collaborative care model
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 27027547

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Number of subjects: 258
Study: 25200513

Group type: EXPERIMENTAL
Intervention: Children born to the most educated mothers
Number of subjects: 12463

Group type: EXPERIMENTAL
Intervention: Children of the most educated mothers
Number of subjects: 12463

Group type: EXPERIMENTAL
Intervention: Children born to the most educated fathers or with a parent in a non-manual occupation
Number of subjects: 12463
Study: 22438600

Group type: EXPERIMENTAL
Intervention: Mock-patient counseling activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer role-play
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written dialogue
Number of subjects: 0
Study: 20642247

Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER)
Number of subjects: 80
Study: 16996808

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Tailored behavioral self-management intervention via telephone by a nurse
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combination of home blood pressure monitoring and tailored behavioral intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study: 15623574

Group type: EXPERIMENTAL
Intervention: High mannan binding lectin (MBL) levels (>1,000 microg/L) in the cross-sectional group (n = 987)
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: High MBL at recruitment in the nested case-control group (n = 1,309)
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: High MBL in diabetic individuals
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: High MBL in hypercholesterolemic individuals
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: High MBL in individuals with raised erythrocyte sedimentation rate
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: High MBL in diabetic patients
Number of subjects: 1309
Study: 12006323

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 272

Group type: COMPARATOR
Intervention: Parenteral gold
Number of subjects: 272
Study: 9710004

Group type: EXPERIMENTAL
Intervention: Patients with degenerative dementia and RBD
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of dementia with Lewy bodies (DLB)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Autopsy findings
Number of subjects: 37
Study: 7794044

Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (THA) 20 mg in 1 ml
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline, 1 ml)
Number of subjects: 84
Study: 2214880

Group type: EXPERIMENTAL
Intervention: 6-month interferon regimen
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3-week interferon trial
Number of subjects: 20
Study: 374428

Group type: EXPERIMENTAL
Intervention: Propoxyphene
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen and propoxyphene
Number of subjects: 32
Study: 30557562

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (40 mg for patients weighing <80 kg and 80 mg for patients weighing ≥80 kg)
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Oseltamivir phosphate
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1109
Study: 28592311

Group type: EXPERIMENTAL
Intervention: Green cardamom (500 mg capsules, three times/day for 3 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (500 mg capsules, three times/day for 3 months)
Number of subjects: 80
Study: 24502675

Group type: EXPERIMENTAL
Intervention: Zirconia implants (Ziterion vario Z(®))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Titanium implants (Ziterion vario T(®))
Number of subjects: 22
Study: 23614370

Group type: EXPERIMENTAL
Intervention: Walking-skill program emphasizing weight-bearing exercises
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 57
Study: 21783385

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (HA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 55
Study: 19264155

Group type: EXPERIMENTAL
Intervention: Minodronate 1 mg once a day for 12 months
Number of subjects: 270

Group type: COMPARATOR
Intervention: Alendronate 5 mg once a day for 12 months
Number of subjects: 270
Study: 16317313

Group type: EXPERIMENTAL
Intervention: ziprasidone 80‐160 mg/day
Number of subjects: 306

Group type: COMPARATOR
Intervention: chlorpromazine 200‐1200 mg/day
Number of subjects: 306
Study: 15316206

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 10898829

Group type: EXPERIMENTAL
Intervention: Tazarotene plus mid-potency corticosteroid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tazarotene plus superpotent corticosteroid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tazarotene
Number of subjects: 0
Study: 9304445

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 52
Study: 8329360

Group type: EXPERIMENTAL
Intervention: Lactose-enriched products (600 g/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mg-enriched products (with added Mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lactose intake (hydrolysis of lactose)
Number of subjects: 24
Study: 3525068

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with AVCF (Adriamycin, vincristine, cyclophosphamide, and 5-fluorouracil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 0
Study: 28971224

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT) sling
Number of subjects: 92

Group type: COMPARATOR
Intervention: Retropubic (RP) sling
Number of subjects: 92
Study: 25758628

Group type: EXPERIMENTAL
Intervention: 100 μg carbetocin shot
Number of subjects: 132

Group type: COMPARATOR
Intervention: 20 IU oxytocin infusion
Number of subjects: 132
Study: 24248532

Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semustine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Temozolomide (with mutant TP53 knockdown)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semustine (with mutant TP53 knockdown)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutant TP53 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MGMT expression
Number of subjects: 0
Study: 22616615

Group type: EXPERIMENTAL
Intervention: Anastrozole and fulvestrant in combination with gefitinib
Number of subjects: 9
Study: 20797953

Group type: EXPERIMENTAL
Intervention: Skin care products (specific products not detailed)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 19023831

Group type: EXPERIMENTAL
Intervention: Gain framed messages with open label sustained-release (SR) bupropion
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Loss framed messages with open label sustained-release (SR) bupropion
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Moderate alcohol use
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Hazardous alcohol use
Number of subjects: 249

Group type: COMPARATOR
Intervention: AUD history
Number of subjects: 249
Study: 16841678

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SI) low dose (0.3 ml/kg)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SI) high dose (0.6 ml/kg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 97
Study: 12636878

Group type: EXPERIMENTAL
Intervention: Once-per-cycle pegfilgrastim 6 mg
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Once-per-cycle pegfilgrastim 100 microg/kg
Number of subjects: 453

Group type: COMPARATOR
Intervention: Daily filgrastim 5 microg/kg
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Both pegfilgrastim and daily filgrastim
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg
Number of subjects: 453
Study: 10812192

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m² iv day 1, Vinorelbine 25 mg/m² iv days 1-8-15-22, Amifostine 740 mg/m² iv day 1 every 4 weeks up to six cycles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cisplatin plus Vinorelbine
Number of subjects: 40
Study: 8859136

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 100
Study: 1644464

Group type: EXPERIMENTAL
Intervention: Pulsed high frequency electromagnetic energy (PHFE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early physiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time of starting treatment
Number of subjects: 0
Study: 6509461

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5, 5, or 10 mg once daily)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg once daily)
Number of subjects: 219
Study: 30525950

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis 420™ (B420), 1010 cfu/d in 12 g microcrystalline cellulose
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Litesse® Ultra™ polydextrose (LU), 12 g/day
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Litesse® Ultra™ polydextrose (LU) + B420, 1010 cfu/d of B420 in 12 g/d LU
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo, 12 g/d microcrystalline cellulose
Number of subjects: 134
Study: 28834534

Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) therapy delivered in twice-weekly 30-minute sessions for 8 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) therapy
Number of subjects: 5
Study: 26725132

Group type: EXPERIMENTAL
Intervention: 1-mm polyethylene (PE) inserts used during total knee arthroplasty
Number of subjects: 88

Group type: COMPARATOR
Intervention: Trial insert sizes (1-mm smaller, same size, and 1-mm larger)
Number of subjects: 88
Study: 25066659

Group type: EXPERIMENTAL
Intervention: Fruit fiber bread
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FibreMax bread
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 80
Study: 21959071

Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol (20 mL of misoprostol solution 1 μg/mL orally every 1 hour for 4 doses then titrated to 40 μg every 1 hour)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional oral misoprostol (50 μg of misoprostol orally every 4 hours up to 12 hours)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (titrated and conventional)
Number of subjects: 64
Study: 19666152

Group type: EXPERIMENTAL
Intervention: Cell-culture-derived influenza vaccine (CCIV)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Egg-based trivalent inactivated influenza vaccine (TIV)
Number of subjects: 1200
Study: 17158048

Group type: EXPERIMENTAL
Intervention: Patient involvement in multidisciplinary meeting
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient attendance at the breast multidisciplinary meeting
Number of subjects: 30
Study: 15522554

Group type: EXPERIMENTAL
Intervention: 5-year tamoxifen administration
Number of subjects: 256

Group type: COMPARATOR
Intervention: 2-year tamoxifen administration
Number of subjects: 256
Study: 11163295

Group type: EXPERIMENTAL
Intervention: Sinemet (25/250 mg)
Number of subjects: 73
Study: 9692700

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.d.; n = 10)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg b.d.; n = 10)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pantoprazole (40 mg b.d.; n = 10)
Number of subjects: 36
Study: 7826791

Group type: EXPERIMENTAL
Intervention: Pethidine 0.75 mg kg‐1 and clonidine 75 micrograms intrathecally
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with morphine 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pethidine-clonidine
Number of subjects: 0
Study: 3293526

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg single dose
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1,000 mg (500 mg doses given 12 h apart)
Number of subjects: 180
Study: 31530046

Group type: EXPERIMENTAL
Intervention: In-hospital physiotherapy treatment (early mobilization, ambulation, breathing exercises, thoracic range of motion exercises)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (not receiving in-hospital physiotherapy treatment)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 107
Study: 29214920

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Placebo perceived as caffeine (PLA)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No supplementation (baseline control)
Number of subjects: 9
Study: 24877892

Group type: EXPERIMENTAL
Intervention: Emotionally evocative PSAs about skin cancer
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Mixed emotional appeals in PSAs
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Audience reactions of fear to PSAs
Number of subjects: 193
Study: 23727830

Group type: EXPERIMENTAL
Intervention: Pre-test measurement of sequential effect before manipulation phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-test measurement of sequential effect after manipulation phase with increased mechanical costs
Number of subjects: 0
Study: 21284702

Group type: EXPERIMENTAL
Intervention: Sitagliptin 5-400mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitagliptin ≥50mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 12
Study: 19170708

Group type: EXPERIMENTAL
Intervention: rhLH 75 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhLH 225 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhCG 250 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhCG 750 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND) suppression
Number of subjects: 0
Study: 16303817

Group type: EXPERIMENTAL
Intervention: Pulsed low-intensity ultrasound therapy (LIUS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 55
Study: 15973019

Group type: EXPERIMENTAL
Intervention: Mycobacterium tuberculosis H37Ra excretory‐secretory antigen (ES‐31) and affinity purified goat anti ES‐31 antibodies
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Detection of circulating free and immune complexed antigen (CIC‐Ag)
Number of subjects: 230
Study: 11960413

Group type: EXPERIMENTAL
Intervention: Talent stent-grafts
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gore-TAG stent-graft
Number of subjects: 16
Study: 9865221

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Case Management (SCM)
Number of subjects: 0
Study: 7622763

Group type: EXPERIMENTAL
Intervention: Salbutamol/CFC-free (100, 200, and 300 micrograms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Salbutamol/CFC (100 and 200 micrograms)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2467781

Group type: EXPERIMENTAL
Intervention: Multicomponent informed consent process utilizing audiovisual and written material as well as behavioral practice
Number of subjects: 0
Study: 51860

Group type: EXPERIMENTAL
Intervention: Counterirritation (10-sec immersion of fingers into a 2 degrees C water bath)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control procedure)
Number of subjects: 18
Study: 30808774

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 4547

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 4547
Study: 28429539

Group type: EXPERIMENTAL
Intervention: Lower intrauterine filling pressures (30, 40, and 50 mmHg)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Higher intrauterine filling pressures (70, 80, and 100 mmHg)
Number of subjects: 175
Study: 26339938

Group type: EXPERIMENTAL
Intervention: Vascular ultrasound
Number of subjects: 382

Group type: COMPARATOR
Intervention: Standard landmark method
Number of subjects: 382
Study: 23323659

Group type: EXPERIMENTAL
Intervention: Directed Self-Regulated Learning (DSRL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Self-Regulated Learning (SRL)
Number of subjects: 37
Study: 21646251

Group type: EXPERIMENTAL
Intervention: CDC's 'Heads Up' toolkit
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group (no toolkit)
Number of subjects: 414
Study: 18796184

Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Naltrexone (all doses)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg and 50 mg)
Number of subjects: 102
Study: 16953990

Group type: EXPERIMENTAL
Intervention: Twice-daily oral hygiene care with 0.12% chlorhexidine gluconate
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard oral care 6 times per day with soft foam swab and half strength hydrogen peroxide
Number of subjects: 5
Study: 15206694

Group type: EXPERIMENTAL
Intervention: Intermittent cyclosporin A therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVAB phototherapy
Number of subjects: 0
Study: 11316172

Group type: EXPERIMENTAL
Intervention: Prazosin 2 mg + Terlipressin 2 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Terlipressin 2 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9141937

Group type: EXPERIMENTAL
Intervention: Nasal CPAP plus oxygen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oxygen by face mask
Number of subjects: 30